Holen Sie sich die Stockscreener-App
46.03
5.37%
2.22
Schlusskurs vom Vortag:
$43.81
Offen:
$43.82
24-Stunden-Volumen:
241.21K
Relative Volume:
0.31
Marktkapitalisierung:
$2.26B
Einnahmen:
$140.49M
Nettoeinkommen (Verlust:
$-153.49M
KGV:
-16.71
EPS:
-2.7551
Netto-Cashflow:
$-175.90M
1W Leistung:
+3.94%
1M Leistung:
-1.68%
6M Leistung:
+131.89%
1J Leistung:
+123.15%
1-Tages-Spanne:
$43.77
$47.06
1-Wochen-Bereich:
$42.50
$47.06
52-Wochen-Spanne:
$15.86
$50.81
Urogen Pharma Ltd Stock (URGN) Company Profile
Firmenname
Urogen Pharma Ltd
Sektor
Branche
Telefon
972 9 770 7601
Adresse
9 HA'TA'ASIYA ST, RA'ANANA
Compare URGN vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
46.28 | 2.14B | 140.49M | -153.49M | -175.90M | -2.7551 |
VRTX
Vertex Pharmaceuticals Inc
|
522.22 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
800.12 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
999.14 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
139.10 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.35 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Jefferies | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-06-16 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-05-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-04-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-19 | Fortgesetzt | Ladenburg Thalmann | Buy |
| 2024-08-22 | Eingeleitet | Guggenheim | Buy |
| 2023-02-08 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-27 | Eingeleitet | Berenberg | Buy |
| 2020-04-16 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-13 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-09 | Eingeleitet | National Securities | Neutral |
| 2019-05-30 | Eingeleitet | JP Morgan | Neutral |
| 2019-05-29 | Eingeleitet | Goldman | Neutral |
| 2019-01-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-08 | Fortgesetzt | Jefferies | Buy |
| 2018-04-04 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-01-02 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-11-15 | Bestätigt | Oppenheimer | Outperform |
| 2017-11-15 | Herabstufung | Raymond James | Outperform → Mkt Perform |
Alle ansehen
Urogen Pharma Ltd Aktie (URGN) Neueste Nachrichten
Urogen Pharma: Upside After Bladder Cancer Launch (NASDAQ:URGN) - Seeking Alpha
UroGen Pharma (NASDAQ: URGN) officer plans 10,000-share sale after RSUs vest - Stock Titan
UroGen Pharma (URGN) officer lines up 5,000-share sale from RSUs - Stock Titan
Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus - Zacks Investment Research
UroGen Pharma (NASDAQ:URGN) Combines High Growth Momentum with a Breakout Setup - ChartMill
UroGen Pharma Ltd (NASDAQ: URGN) Share Price, URGN Stock News, URGN Share Price & Updates - Kalkine
Nineteen new employees could receive up to 117,100 UroGen shares over three years. - Stock Titan
URGN Stock Price, Quote & Chart - ChartMill
UroGen Pharma Ltd. (URGN) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Trading the Move, Not the Narrative: (URGN) Edition - Stock Traders Daily
UroGen will speak at three investor events in September - Stock Titan
IntraGel Therapeutics Receives $7M Investment From UroGen Pharma - FinSMEs
UroGen Pharma Ltd. (URGN) Peer Comparison – Compare with Others - Value Research
UroGen Pharma Ltd. (URGN) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Trade Alert: Chief Medical Officer Of UroGen Pharma Mark Schoenberg Has Sold Stock - Sahm
UroGen Pharma (URGN) Faces A Valuation Test Following Its FDA Filing - Sahm
UGN-103 NDA Filing for Recurrent Bladder Cancer Might Change The Case For Investing In UroGen Pharma (URGN) - Sahm
Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 27.14%: Read This Before Placing a Bet - Yahoo Finance
UroGen Pharma inks licensing deal with IntraGel Therapeutics - The Pharma Letter
UroGen Pharma Enters Option and Investment Deal with IntraGel Therapeutics - Kalkine Media
UroGen (NASDAQ: URGN) officer sold $750K in stock, plans more - Stock Titan
Cancer treatment co UroGen invests $7m in Israel’s IntraGelGlobes - Globes - Israel Business News
INTRAGEL THERAPEUTICS LTD announced that it expects to receive $7 million in funding from UroGen Pharma Ltd. - marketscreener.com
UroGen Pharma secures option deal with IntraGel for cancer tech By Investing.com - Investing.com Nigeria
IntraGel secures $7M from UroGen for cancer therapy development By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates UroGen Pharma stock rating on NDA filing By Investing.com - Investing.com Canada
UroGen Signs Investment, Collaboration Agreements With IntraGel for Access to Sustained-Release Platform - marketscreener.com
URGN Looks 90.6% Overvalued on GF Value™ - GuruFocus
UroGen inks equity and option deals with IntraGel (URGN:NASDAQ) - Seeking Alpha
UroGen Pharma secures option to license IntraGel SRGel program, agrees up to $7M investment - TradingView
UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline - The Manila Times
IntraGel's head and neck cancer drug study gets up to $7 million for Phase 2 - Stock Titan
UroGen gets an exclusive option on TumoCure after Phase 2 - Stock Titan
Urogen Pharma stock hits 52-week high at 49.69 USD By Investing.com - Investing.com South Africa
Urogen Pharma (NASDAQ:URGN) Reaches New 1-Year HighHere's What Happened - MarketBeat
Urogen Pharma stock hits 52-week high at 49.69 USD - Investing.com
UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC - Sahm
Rice Hall James & Associates LLC Purchases Shares of 300,650 Urogen Pharma $URGN - MarketBeat
The Manufacturers Life Insurance Company Has $196,000 Stock Holdings in Urogen Pharma $URGN - MarketBeat
UroGen Pharma Submits US FDA New Drug Application for UGN-103 in Recurrent Bladder Cancer - marketscreener.com
UroGen submits FDA application for bladder cancer drug UGN-103 By Investing.com - Investing.com India
URGN Looks 84.5% Overvalued on GF Value™ - GuruFocus
UroGen submits FDA application for bladder cancer drug UGN-103 - Investing.com
Ninety-nine patients entered a bladder cancer trial—what came next? - Stock Titan
NDA Is Submitted for UGN-103 for Recurrent Low-Grade Intermediate-Risk NMIBC - OncLive
California State Teachers Retirement System Grows Stock Holdings in Urogen Pharma $URGN - MarketBeat
Is UroGen Pharma (URGN) Overvalued As Sales Growth And Patent Clarity Lift Confidence? - simplywall.st
Are You Looking for a Top Momentum Pick? Why Urogen Pharma (URGN) is a Great Choice - Yahoo Finance
UroGen Pharma Ltd (URGN) Competitors 2026 - GuruFocus
(URGN) Volatility Zones as Tactical Triggers - Stock Traders Daily
UroGen (URGN) Q2 2026 Earnings Call Transcript - AOL.com
Finanzdaten der Urogen Pharma Ltd-Aktie (URGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):